Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01200329 · ClinicalTrials.gov registry record · Phase 2
High-Dose Gemcitabine, Busulfan and Melphalan for Patients With Refactory Hodgkin's Disease
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 81
- Enrollment target
NCT01200329: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT01200329 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 81 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01200329, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 81 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if the combination of gemcitabine, busulfan, and melphalan, when given before a stem cell transplant, can help to control refractory Hodgkin's disease. The safety of this study treatment will also be studied.
Interventions
- DRUG Melphalan
- DRUG Busulfan
- DRUG Gemcitabine
- DRUG Palifermin
- PROCEDURE Stem Cell Transplantation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2011-06 |
| Est. Completion | 2018-12-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01200329
The ClinicalTrials.gov registry entry for NCT01200329 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Melphalan is the first listed.
NCT01200329 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01200329 about?
NCT01200329 is a clinical study titled "High-Dose Gemcitabine, Busulfan and Melphalan for Patients With Refactory Hodgkin's Disease". The goal of this clinical research study is to learn if the combination of gemcitabine, busulfan, and melphalan, when given before a stem cell transplant, can help to control refractory Hodgkin's disease. The safety of this study treatment will also be studied.
What is the current status of trial NCT01200329?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 81 participants. The study started on 2011-06. Estimated completion is 2018-12-06.
What interventions are being tested in trial NCT01200329?
The interventions under investigation include: Melphalan (DRUG), Busulfan (DRUG), Gemcitabine (DRUG), Palifermin (DRUG), Stem Cell Transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT01200329?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.